FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214144113> ?p ?o ?g. }

• W3214144113 endingPage "3774" @default.
• W3214144113 startingPage "3774" @default.
• W3214144113 abstract "Abstract Background: The use of immunotherapeutic agents in multiple myeloma (MM) has shown improvements in clinical outcomes, emphasizing the role the host immune system plays in disease control. In recognition of this relationship, efforts aimed at identifying biomarkers of immune surveillance in MM have identified prognostic value in the peripheral absolute lymphocyte (ALC) and absolute monocyte (AMC) counts at various stages of disease and following autologous stem cell transplant (ASCT), with lower ALC and AMC serving as a surrogate for immune dysregulation and correlating with inferior progression free (PFS) and overall survival (OS). With ASCT remaining the standard of care in the treatment of MM, we sought to examine whether CD3 content of the apheresis product during stem cell collection could be used as a biomarker for immune competence and whether it influences outcomes. Methods: A retrospective study was conducted on 1086 MM patients who underwent stem cell (CD34) collection with available CD3 data and subsequent ASCT at our institution. We recorded the total absolute CD3 and CD34 cell count upon completion of mobilization, with a higher CD3 count serving as a surrogate for immune competence. In addition to investigating the absolute CD3 count, we calculated the CD3/CD34 ratio given variation in the CD34 goals. Patients were dichotomized based on whether their absolute CD3 and CD3/CD34 ratio values were above or below medians. A Kaplan-Meier model was used to compare median PFS and OS between groups. A cox proportional hazards model was used to determine its prognostic impact, adjusting for ISS stage 3, high risk FISH, achievement of CR near day 100, and maintenance therapy received post-ASCT. Results: The median length of follow-up from date of ASCT for the entire cohort (N=1086) was 34.1 months (range: 0.26-157 months) and the median time from stem cell collection to ASCT was 9 days (range: 3-3143 days). The most common mobilizing regimen was Neupogen and plerixafor (N=425, 39%) and 694 (64%) patients received ASCT in the first line setting. The median absolute total CD3 count was 4.3 x 10^6/kg (range: 0.1-21.9) with 542 patients above and 544 patients at or below the median. The median absolute total CD34 count was 8.53 x 10^6/kg (range: 0.2-37.0) and median CD3/CD34 ratio was 0.50 (range: 0.01-15), with 536 patients above and 550 patients at or below the median ratio. The median PFS among patients with a CD3 count &gt; 4.25 x 10^6/kg was 23.1 vs. 16.9 months among patients with CD3 count ≤ 4.25 x 10^6/kg (p&lt;0.0001) and median OS was 65.3 months vs. 41.6 months (p&lt;0.0001), respectively. A similar trend was observed when dividing patients based on CD3/CD34 ratio, with median PFS of 22.4 vs. 17.5 months (p=.0003) and median OS of 61.5 vs. 45.7 months (p=.0001), both favoring the cohort with a CD3/CD34 ratio &gt; 0.5 (Figure 1). The prognostic value among patients with a CD3/CD34 ratio &gt; 0.5 was retained after adjusting for ISS stage III, high risk FISH features, and use of maintenance therapy as follows: PFS HR: 0.73 (95% CI: 0.62-0.86; p=0.0002); OS 0.71 (95% CI: 0.59-0.88; p=0.001). Conclusions: Our study demonstrates that patients who have higher CD3 content in their apheresis product have better PFS and OS following ASCT. These findings reveal a possible role for using absolute CD3 and CD3/CD34 ratios in the apheresis product as a surrogate marker for immune competence and in predicting clinical outcomes. Figure 1 Figure 1. Disclosures Gertz: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena: Consultancy; Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme: Honoraria; Aurora Biopharma: Other: Stock option; AbbVie Inc, Celgene Corporation: Other: Data Safetly & Monitoring; Ionis Pharmaceuticals: Other: Advisory Board. Dingli: GSK: Consultancy; Sanofi: Consultancy; Janssen: Consultancy; Alexion: Consultancy; Apellis: Consultancy; Novartis: Research Funding. Dispenzieri: Takeda: Research Funding; Pfizer: Research Funding; Alnylam: Research Funding; Oncopeptides: Consultancy; Sorrento Therapeutics: Consultancy; Janssen: Consultancy, Research Funding. Kapoor: Sanofi: Research Funding; Takeda: Research Funding; Ichnos Sciences: Research Funding; Glaxo SmithKline: Research Funding; Regeneron Pharmaceuticals: Research Funding; AbbVie: Research Funding; Karyopharm: Research Funding; Karyopharm: Consultancy; Cellectar: Consultancy; BeiGene: Consultancy; Pharmacyclics: Consultancy; Sanofi: Consultancy; Amgen: Research Funding. Kumar: Novartis: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Consultancy, Honoraria; Tenebio: Research Funding; Amgen: Consultancy, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bluebird Bio: Consultancy; BMS: Consultancy, Research Funding; Oncopeptides: Consultancy; Carsgen: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche-Genentech: Consultancy, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Consultancy; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding." @default.
• W3214144113 created "2021-11-22" @default.
• W3214144113 creator A5000308170 @default.
• W3214144113 creator A5001453763 @default.
• W3214144113 creator A5012403700 @default.
• W3214144113 creator A5012884078 @default.
• W3214144113 creator A5026574827 @default.
• W3214144113 creator A5033220547 @default.
• W3214144113 creator A5047421947 @default.
• W3214144113 creator A5056260546 @default.
• W3214144113 creator A5068637846 @default.
• W3214144113 creator A5071714331 @default.
• W3214144113 creator A5074505099 @default.
• W3214144113 creator A5076611748 @default.
• W3214144113 creator A5082968253 @default.
• W3214144113 date "2021-11-05" @default.
• W3214144113 modified "2023-09-29" @default.
• W3214144113 title "Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant" @default.
• W3214144113 doi "https://doi.org/10.1182/blood-2021-151439" @default.
• W3214144113 hasPublicationYear "2021" @default.
• W3214144113 type Work @default.
• W3214144113 sameAs 3214144113 @default.
• W3214144113 citedByCount "1" @default.
• W3214144113 countsByYear W32141441132023 @default.
• W3214144113 crossrefType "journal-article" @default.
• W3214144113 hasAuthorship W3214144113A5000308170 @default.
• W3214144113 hasAuthorship W3214144113A5001453763 @default.
• W3214144113 hasAuthorship W3214144113A5012403700 @default.
• W3214144113 hasAuthorship W3214144113A5012884078 @default.
• W3214144113 hasAuthorship W3214144113A5026574827 @default.
• W3214144113 hasAuthorship W3214144113A5033220547 @default.
• W3214144113 hasAuthorship W3214144113A5047421947 @default.
• W3214144113 hasAuthorship W3214144113A5056260546 @default.
• W3214144113 hasAuthorship W3214144113A5068637846 @default.
• W3214144113 hasAuthorship W3214144113A5071714331 @default.
• W3214144113 hasAuthorship W3214144113A5074505099 @default.
• W3214144113 hasAuthorship W3214144113A5076611748 @default.
• W3214144113 hasAuthorship W3214144113A5082968253 @default.
• W3214144113 hasConcept C10205521 @default.
• W3214144113 hasConcept C126322002 @default.
• W3214144113 hasConcept C141341695 @default.
• W3214144113 hasConcept C143998085 @default.
• W3214144113 hasConcept C203014093 @default.
• W3214144113 hasConcept C2776364478 @default.
• W3214144113 hasConcept C2776738589 @default.
• W3214144113 hasConcept C2779050716 @default.
• W3214144113 hasConcept C28328180 @default.
• W3214144113 hasConcept C54355233 @default.
• W3214144113 hasConcept C71924100 @default.
• W3214144113 hasConcept C86803240 @default.
• W3214144113 hasConcept C89560881 @default.
• W3214144113 hasConcept C90924648 @default.
• W3214144113 hasConceptScore W3214144113C10205521 @default.
• W3214144113 hasConceptScore W3214144113C126322002 @default.
• W3214144113 hasConceptScore W3214144113C141341695 @default.
• W3214144113 hasConceptScore W3214144113C143998085 @default.
• W3214144113 hasConceptScore W3214144113C203014093 @default.
• W3214144113 hasConceptScore W3214144113C2776364478 @default.
• W3214144113 hasConceptScore W3214144113C2776738589 @default.
• W3214144113 hasConceptScore W3214144113C2779050716 @default.
• W3214144113 hasConceptScore W3214144113C28328180 @default.
• W3214144113 hasConceptScore W3214144113C54355233 @default.
• W3214144113 hasConceptScore W3214144113C71924100 @default.
• W3214144113 hasConceptScore W3214144113C86803240 @default.
• W3214144113 hasConceptScore W3214144113C89560881 @default.
• W3214144113 hasConceptScore W3214144113C90924648 @default.
• W3214144113 hasIssue "Supplement 1" @default.
• W3214144113 hasLocation W32141441131 @default.
• W3214144113 hasOpenAccess W3214144113 @default.
• W3214144113 hasPrimaryLocation W32141441131 @default.
• W3214144113 hasRelatedWork W1895328588 @default.
• W3214144113 hasRelatedWork W2022355235 @default.
• W3214144113 hasRelatedWork W2057617035 @default.
• W3214144113 hasRelatedWork W2058161955 @default.
• W3214144113 hasRelatedWork W2106084785 @default.
• W3214144113 hasRelatedWork W2156425432 @default.
• W3214144113 hasRelatedWork W2569949963 @default.
• W3214144113 hasRelatedWork W2888500901 @default.
• W3214144113 hasRelatedWork W2979715556 @default.
• W3214144113 hasRelatedWork W4310119485 @default.
• W3214144113 hasVolume "138" @default.
• W3214144113 isParatext "false" @default.
• W3214144113 isRetracted "false" @default.
• W3214144113 magId "3214144113" @default.
• W3214144113 workType "article" @default.